Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, February 6, 2013 Hospira Inc (NYSE:HSP), Up By 5.45% ($1.86) From $34.140 After BUYINS.NET Report Predicted Strength Before Earnings
February 6, 2013 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, February 5th 2013 stating that Hospira Inc (NYSE:HSP) was expected to be Up Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=hsp&id=345402
At the time this story was written, Hospira Inc (NYSE:HSP) is Up By 5.45% ($1.86) From $34.140 since the BUYINS.NET report was released.
The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php
Hospira Inc (NYSE:HSP) - Hospira, Inc. provides injectable drugs and infusion technologies to develop, manufacture, distribute, and markets products that help improve the safety of patient care worldwide. The company offers specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; proprietary specialty injectables, including Precedex, a proprietary drug for sedation; Biosimilars that comprise Retacrit, a biosimilar erythropoietin, which is used primarily in the treatment of anemia in dialysis and in certain oncology applications; and ; and Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent. It also provides intravenous solutions and nutritional products; and contract manufacturing services. In addition, the company offers medication management products consisting of infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, it is involved in the development/co-development of proprietary pharmaceutical products, such as Precedex, which is in Phase III clinical trial for procedural sedation; POSIDUR, a long-acting version of the anesthetic bupivacaine that is in Phase III clinical trial; Dyloject, a post-operative pain management drug; and ATIR, a personalized hematology product designed for blood cancer patients in need of allogeneic bone marrow transplantation who cannot locate a matched donor. The company serves hospitals, clinics, home healthcare providers, and long-term care facilities. It has various collaborative arrangements with Kiadis Pharma B.V.; DURECT Corporation; ChemGenex Pharmaceuticals Limited; and Bioceuticals Arzneimittel AG. The company was founded in 2003 and is headquartered in Lake Forest, Illinois..
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.
INVESTMENTS & TRADING
SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.
GATS -- tracks and quantifies known trading strategies.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Hospira Inc (NYSE:HSP) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net
- WOPRAI
- support@woprai.com